[Effect of continuous blood purification and thymosin alpha1 on the cellular immunity in patients with severe sepsis: a prospective, randomized, controlled clinical trial]

Plain-language guide to PMID 19278581 (2009): randomized controlled trial study of Thymosin Alpha-1, cellulite.

Key Facts

PMID: 19278581
Journal: Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue
Year: 2009
Study type: Randomized Controlled Trial
Authors: Li YN et al. (10 authors)

What This Study Did, in Plain Language

What Was Tested

Researchers studied Thymosin Alpha-1 in the context of cellulite in this randomized controlled trial publication.

To discuss the effect of continuous blood purification (CBP), thymosin alpha1 and combined therapy on cellular immunity in patients with severe sepsis.

Who Took Part

Ninety-one patients, age over 18 years, suffering from severe sepsis with Marshall score over 5, admitted to the intensive care unit (ICU) from June, 2004 to October, 2007, were randomly divided into four groups.

The patients in control group (24 cases) were treated with classical Surviving Sepsis Campaign (SSC) therapy, those in CBP group (22 cases) were treated with continuous renal replacement therapy (CRRT) or molecular adsorbent recirculating system (MARS) in the first 3 days.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Thymosin Alpha-1 and who got the comparison, which limits bias.

The patients in the group of combined therapy (22 cases) were treated with CBP and thymosin alpha1.

All three treatment groups were treated with classical SSC therapy at the same time.

Acute physiology and chronic health evaluation II (APACHE II) score and Marshall score were evaluated.

CD14(+) monocyte human leucocyte antigen DR (HLA-DR) levels and the count of T lymphocyte were measured before treatment and 3 days and 7 days after the treatment.

What Was Measured

PubMed files the paper under topics including Immunity, Cellular, Prognosis, Sepsis, Thymalfasin and Thymosin.

What This Means in Plain Language

The paper is a randomized study of Thymosin Alpha-1 in people with cellulite.

Results are reported in around 11 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2009 (Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue), a journal based in China.

More context: the Thymosin Alpha-1 compound page, Cellulite research.

Our Notes on the Compound

Thymosin Alpha-1: An immune-modulating thymic peptide that recalibrates T-cell function.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.